To homepage
820К+ patients have got assistance since 2014
50 countries
1,500 clinics
6K+ reviews
3K+ qualified doctors

What's the Cost of Leukemia Diagnosis and Treatment in China?

The price is provided on request
ChinaTurkeyAustria
Chemotherapy for breast cancerfrom $14,800from $1,200from $15,000
CAR T-cell therapyfrom $165,000from $150,000from $350,000
Leukemia chemotherapyfrom $16,500from $8,000from $15,000
Therapeutic Apheresisfrom $2,500from $1,350-
Data verified by Bookimed as of May 2026, based on patient requests and official quotes from 104 clinics worldwide. Median costs are based on real invoices (2025–2026) and updated monthly. Actual prices may vary.

Your Benefits and Guarantees with Bookimed

Transparent Prices & Flexible Installments

No hidden fees – just official clinic prices. Pay at the clinic for Leukemia treatment and use a flexible installment plan if needed.

Verified Clinics & Doctors Only

Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Leukemia treatment and have the necessary licenses to serve international patients worldwide.

Free 24/7 Assistance

Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Leukemia treatment journey.

Why we?

Your personal Bookimed medical coordinator

  • Supports you at every stage
  • Helps choose the right clinic and doctor
  • Ensures quick and convenient access to information

Best Leukemia Treatment Centers in China: 1 Verified Option and Prices

The Bookimed clinic ranking is based on data science algorithms, providing a trusted, transparent, and objective comparison. It takes into account patient demand, review scores (both positive and negative), the frequency of updates to treatment options and prices, response speed, and clinic certifications.

Get a Medical Assessment for Leukemia in China: Consult with Experienced Doctors Now

View all Doctors

Related Articles

Share this content

Video Stories from Bookimed Patients

Dayana
I combined my vacation in Antalya with a check-up.
Procedure: Female check-up
Igor
It was great! Transfers, accommodation, treatment—all included.
Procedure: Dental Implant
Marina
Bookimed did everything for me. I didn't have to worry about anything.
Procedure: Female check-up
Updated: 05/27/2022
Authored by
Anna Leonova
Anna Leonova
Head of Content Marketing Team
A certified medical writer with 10+ years of experience, developed Bookimed’s trusted content, backed by a Master’s in Philology and medical expert interviews worldwide.
Fahad Mawlood
Medical Editor & Data Scientist
General practitioner. Winner of 4 scientific awards. Served in Western Asia. Former Team Leader of a medical team supporting Arabic-speaking patients. Now responsible for data processing and medical content accuracy.
Fahad Mawlood Linkedin
This page may feature information relating to various medical conditions, treatments, and healthcare services available in different countries. Please be advised that the content is provided for informational purposes only and should not be construed as medical advice or guidance. Please consult with your doctor or a qualified medical professional before starting or changing medical treatment.

Expert Overview about Leukemia Treatment in China

These FAQs come from real patients seeking medical assistance through Bookimed. Answers are given by experienced medical coordinators and trusted clinic representatives.

What advanced leukemia treatments are uniquely available or pioneered in China?

China pioneered the world first cure for acute promyelocytic leukemia using differentiation therapy. It also leads in cellular immunotherapy with the largest volume of active CAR-T trials. Leading centers utilize the Beijing Protocol for high-success haploidentical stem cell transplants from family donors.

  • Beijing Protocol: Enables successful `half-matched` family donor transplants for patients lacking full matches.
  • Pioneering therapy: Employs ATRA and arsenic trioxide to reach 95% survival in APL.
  • CAR-T innovations: Offers dual-target therapies (CD19/CD22) and rapid cell manufacturing within 36 hours.
  • Inaticabtagene autoleucel: First domestic CAR-T therapy approved for B-cell acute lymphoblastic leukemia.

Bookimed Expert Insight: China is a leader in pediatric hematology cases due to high patient volumes. Dr. Xiao Juan at Beijing Kyoto Children Hospital brings over 20 years of experience to high-risk infant leukemia. This deep expertise often allows Chinese specialists to accept complex cases that other international centers might decline.

Patient Consensus: Patients note that China provides faster access to experimental combinations and bispecific antibodies through clinical trials. Many emphasize the importance of choosing established Beijing or Shanghai centers that offer dedicated English-language support.

What is the survival-rate comparison between China and Western countries for key types of leukemia?

Chinese leukemia survival rates vary significantly by type. Specific protocols for childhood Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia now match or exceed Western benchmarks. While national averages often trail Global North standards, urban specialty hematology centers report comparable outcomes using advanced therapies.

  • Childhood leukemia: 5-year survival for pediatric ALL reaches 85% to 91% in urban centers.
  • Adult leukemia: Adult AML survival remains lower at 24% for national Chinese averages.
  • Chronic lymphocytic: Chinese patients show 85% 5-year survival with targeted therapies versus 65% elsewhere.
  • Cellular immunotherapy: Access to CAR T-cell therapy boosts survival by 20% to 30% for refractory cases.

Bookimed Expert Insight: Data reveals a survival advantage in China specifically for patients seeking CAR T-cell therapy. While Western centers follow standardized drug approvals, Beijing centers like GoBroad Boren Hospital provide rapid access to these trials. A CAR-T package costs approximately $100,250 and includes 30 days of hospitalization. This extensive inpatient monitoring explains why urban success rates for complex cases rival top-tier American institutions.

Patient Consensus: Patients note that seeking care in Tier-1 city hospitals is vital for matching Western success rates. Those participating in clinical trials report significantly better outcomes for difficult, relapsed cases than with standard chemotherapy.

How does Traditional Chinese Medicine (TCM) integrate with modern leukemia therapy in China?

China integrates Traditional Chinese Medicine (TCM) with modern leukemia therapy by combining Western protocols like chemotherapy and CAR T-cell therapy with herbal adjuncts. This multimodal approach uses TCM to mitigate toxicity, boost immune recovery, and improve survival rates. Major Class A Level III hospitals in Beijing coordinate these integrated treatments.

  • Adjuvant support: Herbs like Astragalus reduce chemotherapy side effects like nausea and fatigue.
  • Derived medications: Arsenic Trioxide and Homoharringtonine are TCM-derived drugs for specific leukemia subtypes.
  • Immune regulation: Fu Zheng therapies help restore hematopoietic function and white blood cell counts.
  • Maintenance care: Practitioners use personalized herbal decoctions to help prevent relapse after clinical remission.

Bookimed Expert Insight: Data from top-tier facilities like Yanda International Hospital show that integration is most effective when performed in JCI-accredited environments. While a CAR T-cell therapy package at specialized centers like Beijing GoBroad Boren Hospital costs around $100,000, the addition of hospital-regulated TCM often focuses on the 30-day recovery phase. Choosing a hospital that manages both ensures that herbal supplements do not interfere with high-tech treatments like CAR T-cell infusions.

Patient Consensus: Patients note it is important to use only hospital-prescribed herbs to avoid liver toxicity. Many find that combining Western chemo with TCM decoctions helps their blood counts recover faster during long-term maintenance.

What is the `Beijing Protocol` for stem-cell transplant and why is it significant?

The Beijing Protocol is a pioneering medical method for haploidentical stem-cell transplantation. It allows patients to receive transplants from family members who are only a 50% genetic match. This technique effectively solves donor shortages by ensuring nearly every patient has a potential donor within their family.

  • Donor accessibility: Parents or siblings can serve as donors regardless of a perfect genetic match.
  • Success rates: Approximately 99% of patients achieve sustained myeloid engraftment using this specialized protocol.
  • Graft management: Surgeons use unmanipulated grafts without removing T-cells outside of the body.
  • Immune tolerance: Precise doses of Anti-Thymocyte Globulin (ATG) help prevent Graft-Versus-Host Disease (GVHD).

Bookimed Expert Insight: This protocol is highly effective for urgent high-risk cases where finding a matched donor takes too long. Beijing GoBroad Boren Hospital and Kyoto Children's Hospital are key hubs for these transplants. While standard CAR-T therapy packages can cost around $100,000, specialized stem-cell protocols often require 30-day hospitalizations for safe engraftment.

Patient Consensus: Patients note that recovery is often faster than expected, with engraftment typically occurring within 14 days. They emphasize the importance of staying in China for two years of follow-up to ensure long-term monitoring is consistent.

What is the typical length of stay for international patients undergoing CAR T-cell therapy in China?

International patients undergoing CAR T-cell therapy in China typically stay for 3 to 8 weeks. This period includes cellular collection, laboratory manufacturing, and post-infusion monitoring. Specialized centers in Beijing and Shanghai often require at least 30 days of direct hospitalization for safety.

  • Hospitalization phase: Packages at Beijing GoBroad Boren Hospital include 30 days of inpatient stay.
  • Manufacturing timeline: T-cell expansion usually takes 14 to 21 days in Chinese laboratories.
  • Monitoring window: Critical observation for cytokine release syndrome lasts 2 to 4 weeks post-infusion.
  • Total duration: Most patients should plan for 2 to 3 months in the country.

Bookimed Expert Insight: While standard CAR-T cell manufacturing takes up to 3 weeks, some Chinese facilities use specialized platforms that reduce this to 36 hours. If you select a clinic with this technology, your overall stay may decrease. However, mandatory monitoring for side effects like neurotoxicity remains strict regardless of how fast cells are produced.

Patient Consensus: Patients emphasize that outpatient CAR-T is rare in China. Most recommend staying within 2 hours of the hospital for several weeks after discharge to manage potential fevers.

Get a free consultation

Select the best way to contact you